Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hepion PharmaceuticalsSTU:3360 33 FCF Yield % is -23.56 as of Sep. 02, 2026. GuruFocus rates STU:3360 with a GF Score™ of 33/100. The stock has 2 warning signs investors should review. Among 1,406 Biotechnology companies, Hepion Pharmaceuticals ranks worse than 70.13% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Hepion Pharmaceuticals FCF Yield % Related Terms
Hepion Pharmaceuticals FCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:3360 vs XCUR, IMNN, SNGX: FCF Yield % Comparison
For the Biotechnology subindustry, Hepion Pharmaceuticals's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hepion Pharmaceuticals FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Hepion Pharmaceuticals's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Hepion Pharmaceuticals's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hepion Pharmaceuticals (STU:3360) has a FCF Yield % of -23.56 as of Sep. 02, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Hepion Pharmaceuticals and its competitors. According to the industry distribution chart, Hepion Pharmaceuticals ranks #986 out of 1406 companies in the Biotechnology industry, placing it in the top 70.1%.
Is Hepion Pharmaceuticals' FCF Yield % too high?
Hepion Pharmaceuticals' current FCF Yield % is -23.56. Based on the distribution chart, Hepion Pharmaceuticals ranks #986 out of 1406 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Hepion Pharmaceuticals has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Hepion Pharmaceuticals' FCF Yield % compare to XCUR and IMNN?
According to the Biotechnology industry distribution chart, Hepion Pharmaceuticals ranks #986 out of 1406 companies for FCF Yield %. This places Hepion Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Hepion Pharmaceuticals and its competitors. Hepion Pharmaceuticals's current FCF Yield % is -23.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hepion Pharmaceuticals stock overvalued right now?
Hepion Pharmaceuticals (STU:3360) has a current FCF Yield % of -23.56. The current FCF Yield % is -23.56. Hepion Pharmaceuticals' overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Hepion Pharmaceuticals (STU:3360), the current FCF Yield % is -23.56 as of Sep. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses on the development of drug therapy for the treatment of chronic liver diseases. The company is pioneering early cancer detection solutions with a novel liquid biopsy. diagnostics. The company's mission is to redefine the early detection of hepatocellular carcinoma, moving from missed diagnoses to timely, precise intervention. It's focused on delivering non-invasive, clinically grounded liquid biopsy solutions for patients at the highest risk, particularly those living with cirrhosis.
33GF Score
Get the complete analysis for STU:3360
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:3360 has been successfully added to your 
